Zydus Lifesciences launches Anyra for advancing ophthalmic care

19 Feb 2026 Evaluate

Zydus Lifesciences has launched Anyra, India’s first indigenously developed biosimilar of Aflibercept 2 mg. The company has also signed an agreement with Regeneron Pharmaceuticals, Inc. and Bayer. Anyra is indicated for the treatment of neovascular (wet) Age-related Macular Degeneration (AMD), visual impairment due to macular edema secondary to Retinal Vein Occlusion (Branch RVO or Central RVO), visual impairment due to Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and visual impairment due to Myopic Choroidal Neovascularization (mCNV). With this launch, the company reinforces its commitment to advancing ophthalmic care and expanding access to high-quality, affordable biologics for patients across India.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.


Zydus Lifesciences Share Price

901.00 -1.25 (-0.14%)
20-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1724.45
Dr. Reddys Lab 1280.30
Cipla 1341.45
Zydus Lifesciences 901.00
Lupin 2219.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×